Table 1.
Baseline profiles of participants in different TG/HDL-C quartiles
| Variable | TG/HDL-C (Q1) (0.19–1.23)(n = 534) |
TG/HDL-C (Q2) (1.24–2.06)(n = 538) |
TG/HDL-C (Q3) (2.07–3.82)(n = 561) |
TG/HDL-C (Q4) (3.83–69.25)(n = 568) |
P-value |
|---|---|---|---|---|---|
| Age (years, mean ± sd) | 59.13 ± 15.27 | 59.41 ± 13.44 | 59.46 ± 12.87 | 59.05 ± 13.25 | 0.949 |
| WBC (109/L, mean ± sd) | 12.28 ± 5.67 | 11.93 ± 5.47 | 12.80 ± 6.03 | 14.72 ± 7.58* | < 0.001 |
| CRP [mg/L, Median (Q1-Q3)] | 96.92 (61.92-157.93) | 103.78 (70.70–166.00) | 112.00 (77.39–187.00)* | 148.00 (90.00-204.50)* | < 0.001 |
| PCT [ng/mL, Median (Q1-Q3)] | 0.88 (0.22–6.30) | 1.01 (0.30–6.54) | 4.60 (0.76–22.08)* | 15.64 (3.97–52.56)* | < 0.001 |
| TBIL [µmol/L, Median (Q1-Q3)] | 14.65 (9.50-22.33) | 13.95 (9.00-22.20) | 15.90 (10.10–27.10)* | 20.25 (12.47–42.62)* | < 0.001 |
| ALB (g/L, mean ± sd) | 34.73 ± 5.08 | 32.73 ± 5.43* | 30.81 ± 5.46* | 27.85 ± 5.64* | < 0.001 |
| ALT [IU/L, Median (Q1-Q3)] | 46.01 (24.00-80.01) | 48.01 (27.00-80.75) | 54.00 (32.00–93.00)* | 77.50 (46.00-128.25)* | < 0.001 |
| AST[IU/L, Median (Q1-Q3)] | 34.02 (22.01–65.25) | 35.01 (21.92-64.00) | 40.00 (25.00–81.00) | 63.00 (35.08–131.00)* | < 0.001 |
| GGT [IU/L, Median (Q1-Q3)] | 99.00 (55.00-178.00) | 130.00 (75.00-224.50)* | 122.00 (74.00-214.00)* | 135.00 (74.00-247.00)* | 0.002 |
| ALP [IU/L, Median (Q1-Q3)] | 121.00 (88.50–175.00) | 140.85 (97.00-209.00)* | 148.00 (109.00-223.50)* | 166.00 (116.00-246.00)* | < 0.001 |
| TG (mmol/L, mean ± sd) | 0.85 ± 0.26 | 1.19 ± 0.35* | 1.60 ± 0.53* | 2.67 ± 1.70* | < 0.001 |
| TC (mmol/L, mean ± sd) | 3.59 ± 1.00 | 3.54 ± 1.04 | 3.35 ± 1.02* | 3.19 ± 1.16* | < 0.001 |
| HDL-C (mmol/L, mean ± sd) | 1.06 ± 0.44 | 0.74 ± 0.22* | 0.58 ± 0.19* | 0.34 ± 0.18* | < 0.001 |
| LDL-C (mmol/L, mean ± sd) | 2.28 ± 0.81 | 2.33 ± 0.90 | 2.08 ± 0.91* | 1.51 ± 0.89* | < 0.001 |
| Apo-A1 (g/L, mean ± sd) | 0.90 ± 0.26 | 0.73 ± 0.23* | 0.62 ± 0.33* | 0.44 ± 0.19* | < 0.001 |
| Apo-B (g/L, mean ± sd) | 0.79 ± 0.32 | 0.86 ± 0.26* | 0.86 ± 0.31* | 0.86 ± 0.30* | < 0.001 |
| TG/HDLC(mean ± sd) | 0.86 ± 0.25 | 1.62 ± 0.23* | 2.82 ± 0.51* | 9.71 ± 8.85* | < 0.001 |
| Cr [µmol/L, Median (Q1-Q3)] | 67.80 (53.30–81.00) | 66.00 (54.30–79.00) | 66.00 (51.10–84.00) | 73.85 (57.00-101.00)* | < 0.001 |
| UA [µmol/L, Median (Q1-Q3)] | 232.50 (169.75-293.25) | 228.00 (162.27-293.93) | 219.00 (161.50-296.30) | 250.00 (187.00-360.12)* | < 0.001 |
| Glu[mmol/L, Median (Q1-Q3)] | 5.91 (4.89–7.90) | 6.81 (5.23–9.59)* | 7.22 (5.48–11.09)* | 8.81 (6.09–13.66)* | < 0.001 |
| HBA1c (%,mean ± sd) | 7.17 ± 2.47 | 7.78 ± 2.58* | 8.23 ± 2.69* | 9.09 ± 2.90* | < 0.001 |
| BMI (kg/m2,mean ± sd) | 23.03 ± 3.46 | 23.50 ± 3.26 | 23.29 ± 3.42 | 23.85 ± 3.44* | 0.011 |
|
Length of hospitalization (days, mean ± sd) |
16.18 ± 9.43 | 16.01 ± 9.11 | 17.12 ± 10.00 | 18.37 ± 10.44* | 0.002 |
| Gender, n (%) | 0.016 | ||||
| Male | 341 (63.86%) | 332 (61.71%) | 360 (64.29%) | 400 (70.42%) | |
| Female | 193 (36.14%) | 206 (38.29%)* | 200 (35.71%) | 168 (29.58%)* | |
| Diabetes mellitus, n (%) | < 0.001 | ||||
| No | 386 (72.28%) | 309 (57.43%) | 290 (51.69%) | 260 (45.77%) | |
| Yes | 148 (27.72%) | 229 (42.57%)* | 271 (48.31%)* | 308 (54.23%)* | |
| Hypertension, n (%) | 0.531 | ||||
| No | 381 (71.35%) | 373 (69.33%) | 404 (72.01%) | 389 (68.49%) | |
| Yes | 153 (28.65%) | 165 (30.67%) | 157 (27.99%) | 179 (31.51%) | |
| Fatty liver, n (%) | 0.014 | ||||
| No | 454 (85.02%) | 429 (79.74%) | 444 (79.14%) | 441 (77.64%) | |
| Yes | 80 (14.98%) | 109 (20.26%)* | 117 (20.86%)* | 127 (22.36%)* | |
| Biliary disease, n (%) | 0.883 | ||||
| No | 335 (62.73%) | 349 (64.87%) | 362 (64.53%) | 361 (63.56%) | |
| Yes | 199 (37.27%) | 189 (35.13%) | 199 (35.47%) | 207 (36.44%) | |
| Cardiovascular diseases, n (%) | 0.435 | ||||
| No | 442 (82.77%) | 450 (83.64%) | 467 (83.24%) | 489 (86.09%) | |
| Yes | 92 (17.23%) | 88 (16.36%) | 94 (16.76%) | 79 (13.91%) | |
| Statin use, n (%) | 0.147 | ||||
| No | 514 (96.25%) | 524 (97.40%) | 550 (98.04%) | 558 (98.24%) | |
| Yes | 20 (3.75%) | 14 (2.60%) | 11 (1.96%) | 10 (1.76%) | |
| Malignancy, n (%) | 0.003 | ||||
| No | 459 (85.96%) | 486 (90.33%) | 508 (90.55%) | 526 (92.61%) | |
| Yes | 75 (14.04%) | 52 (9.67%)* | 53 (9.45%)* | 42 (7.39%)* | |
WBC white blood cell count, CRPC-reactive protein, PCT procalcitonin, TBIL total bilirubin, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Apo-A1 Apolipoprotein-A1, Apo-B Apolipoprotein-B, Cr creatinine, UA uric acid, Glu glucose, HBA1c hemoglobin A1c, BMI Body mass index
Values are n (%) or mean ± SD or median (quartile)
Q1 serves as the reference. * P < 0.05